Currently, there are 267.74M common shares owned by the public and among those 259.36M shares have been available to trade.
The company’s stock has a 5-day price change of 0.00% and 29.77% over the past three months. PACB shares are trading -82.67% year to date (YTD), with the 12-month market performance down to -79.32% lower. It has a 12-month low price of $1.16 and touched a high of $10.65 over the same period. PACB has an average intraday trading volume of 8.98 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -3.04%, 2.62%, and -49.74% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Pacific Biosciences of California Inc (NASDAQ: PACB) shares accounts for 84.02% of the company’s 267.74M shares outstanding.
It has a market capitalization of $463.30M and a beta (3y monthly) value of 2.05. The earnings-per-share (ttm) stands at -$1.50. Price movements for the stock have been influenced by the stock’s volatility, which stands at 5.79% over the week and 9.40% over the month.
Earnings per share for the fiscal year are expected to increase by 5.17%, and 40.05% over the next financial year. EPS should grow at an annualized rate of -1.00% over the next five years, compared to -9.76% over the past 5-year period.
Looking at the support for the PACB, a number of firms have released research notes about the stock. Jefferies stated their Buy rating for the stock in a research note on June 03, 2024, with the firm’s price target at $4. Goldman was of a view on April 18, 2024 that the stock is Neutral, while Stephens gave the stock Overweight rating on December 14, 2023, issuing a price target of $11. Guggenheim on their part issued Neutral rating on December 14, 2023.
